Novartis (Ireland)

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017

Mary B. Daly, Robert Pilarski, Michael P. Berry et al. · Journal of the National Comprehensive Cancer Network · 2016 · 647 citations · Full text

Family Medicine, Genetic Testing, Breast Oncology +24

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial

Theodore W. Laetsch, Shannon L. Maude, Susana Rives et al. · Journal of Clinical Oncology · 2022 · 314 citations · Full text

Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection

Daniele Accapezzato, Vittorio Francavilla, Marino Paroli et al. · Journal of Clinical Investigation · 2004 · 300 citations · Full text

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi et al. · The Lancet · 2023 · 270 citations

Inflammation, Double-blind Phase 3, Week 16 +5

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial

Kenneth R. Chapman, John R. Hurst, Stefan Frent et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 256 citations